28 Aug 2020 --- IFF shareholders have voted to approve the issuance of shares of IFF common stock in relation to the company’s upcoming merger with DuPont’s Nutrition & Biosciences (N&B) business. The transaction remains on track and is due to close in the first quarter of 2021, subject to regulatory approvals and conditions. DuPont has also published its second quarter 2020 results, which reveal strong growth in the probiotics business, despite N&B’s net sales being down 1 percent from the year-ago period.
